On this page
- What oncology infusion billing involves
- Who this affects
- Common codes and what they usually mean
- The infusion hierarchy, units, and wastage
- Hierarchy
- Units, NDC, and wastage
- Prior authorization and benefit type
- Common denial patterns
- Investigation steps when claims go unpaid
- How Mednex works with oncology practices
- Mednex and practice responsibilities
- Records and access needed
- Quality checks and exceptions
- How progress is measured
- What cannot be promised
- Sources to verify
- Frequently asked questions
- What do oncology infusion billing services include?
- How is this different from general oncology billing?
- What is the infusion hierarchy?
- How are infusion drugs billed?
- Why do oncology drug claims get denied?
- How is oncology infusion billing priced?
- Next steps
What oncology infusion billing involves
An infusion visit generates an administration record — what was infused, in what order, for how long — and a drug record with agents, doses, and vial sizes. Billing turns that into a claim that follows the infusion hierarchy (one initial service per encounter, with sequential, concurrent, and additional-hour add-ons) and reports each drug by exact units with NDC and wastage. Because the drugs dominate the cost and are paid under the medical benefit, drug-unit and wastage accuracy is where the money is. General oncology E/M and office billing is covered on the oncology billing page; this page is specific to infusion and drug administration.
Who this affects
Medical oncology and hematology practices, infusion centers, and multispecialty groups with an infusion suite. These are the claims where a recurring error — the wrong initial-versus-sequential code, miscounted drug units, a missing wastage modifier — multiplies across every infusion at high dollar value, and where buy-and-bill means the practice carries drug cost until the claim pays.
Common codes and what they usually mean
Confirm current descriptors, the infusion hierarchy, and payer policy before billing; this is orientation.
- 96413 — chemotherapy intravenous infusion, up to one hour, single or initial substance.
- 96415 — each additional hour of chemotherapy infusion (add-on).
- 96417 — each additional sequential infusion of a different drug (add-on).
- 96360 / 96361 — hydration, initial and each additional hour.
- 96365–96368 — therapeutic/non-chemo infusions, initial, additional, sequential, and concurrent.
- Drug J-codes with NDC, and modifiers JW / JZ — the agents billed by exact units, with wastage reported (JW) or attested as none (JZ).
The hierarchy allows one initial service per encounter; everything else is sequential, concurrent, or additional-hour. Coding two initial services, or billing sequential drugs as initial, is a classic error.
The infusion hierarchy, units, and wastage
Hierarchy
Each encounter has a single initial infusion code, chosen by the primary reason for the visit, with additional drugs reported as sequential or concurrent and additional time as add-on hours. Hydration is bundled or separate depending on the circumstances. The administration record has to support the order and timing billed.
Units, NDC, and wastage
Drugs are billed by defined units with the NDC, and discarded drug from single-use vials is reported with the JW modifier (JZ when none). Payers audit wastage and units closely because the dollar amounts are large, so the units billed have to match the dose and vial exactly.
Prior authorization and benefit type
Oncology drugs frequently require prior authorization and may be subject to step therapy or pathway requirements, and some are covered under the pharmacy benefit rather than the medical benefit depending on the plan. An agent given outside authorization, or billed under the wrong benefit, denies — and because the drug is already infused, the practice carries the loss. Confirming authorization and the benefit path before the infusion is central.
Common denial patterns
- Infusion-hierarchy errors — two initial services, or sequential drugs billed as initial.
- Drug-unit errors — units not matching the dose and vial.
- Wastage modifier errors — JW/JZ missing or inconsistent.
- Missing authorization or pathway — drug not authorized or off the required pathway.
- Benefit mismatch — drug billed medical where pharmacy benefit was required.
- Hydration bundling — hydration billed separately when it was bundled.
Investigation steps when claims go unpaid
The check runs in order: confirm drug authorization, pathway, and the benefit path; confirm the infusion hierarchy matches the administration record; confirm drug units, NDC, and wastage; confirm hydration handling; then review the E/M and same-day services. Oncology infusion denials concentrate in authorization, hierarchy, and drug units, so those come first.
How Mednex works with oncology practices
Mednex manages drug authorization and the benefit path before infusions, codes the infusion hierarchy to the administration record, reports drug units with NDC and the correct wastage modifier, and works the drug and hierarchy denials. Denials are worked to root cause and the practice gets reporting on denial reasons and on drug-cost exposure in A/R. Mednex works inside the existing EHR and oncology practice-management system.
Mednex and practice responsibilities
Mednex does not administer drugs, decide treatment, or manage inventory. Mednex secures authorization, bills the infusion and drugs accurately, and works denials. The practice owns the clinical care, administration, and inventory. Mednex is not a law firm; drug-coverage disputes that become legal matters are for the practice’s counsel.
Records and access needed
- Access to the EHR and oncology practice-management system.
- Administration records with drugs, order, timing, doses, and vial sizes.
- Authorization records, pathway requirements, and benefit-type details by payer.
- The payer mix and relevant drug coverage policies.
No protected health information is collected through this website. When records are needed, they move through a secure workflow under a signed business associate agreement.
Quality checks and exceptions
Before submission, claims are checked for authorization and benefit path, infusion-hierarchy accuracy, and drug units and wastage. Exceptions — a regimen change, a pathway question, a high-wastage vial — are flagged for review before the infusion where possible.
How progress is measured
Performance is measured on clean-claim rate, drug-unit and wastage accuracy, authorization capture, and drug-cost exposure in aging A/R — not on a revenue promise. These show whether the gap is authorization, hierarchy, or drug units.
What cannot be promised
- That a payer will authorize or cover a given drug or regimen.
- That a specific amount of revenue will result.
- That a drug given outside authorization or the required benefit path will be paid.
- That a pathway or step-therapy denial will overturn on appeal.
Sources to verify
Infusion codes, the hierarchy, drug units, and wastage rules change. Before relying on any statement here for a claim, verify against current primary sources: the Medicare Physician Fee Schedule and ASP drug files, CMS infusion and JW/JZ guidance, the CMS Medicare Coverage Database, and the specific payer’s drug and pathway policy.
Frequently asked questions
What do oncology infusion billing services include?
Drug authorization and benefit-path management, coding the infusion hierarchy to the administration record, reporting drug units with NDC and the correct wastage modifier, submitting claims, and working drug and hierarchy denials.
How is this different from general oncology billing?
General oncology billing covers office visits and evaluation and management; infusion billing is dominated by the infusion-administration hierarchy and high-cost drugs billed by exact units with wastage under the medical benefit, which carry different and higher-stakes rules.
What is the infusion hierarchy?
Each encounter has one initial infusion service, with other drugs reported as sequential or concurrent and additional time as add-on hours. Billing two initial services or mis-ordering the drugs is a common denial.
How are infusion drugs billed?
By exact units with the NDC, and any discarded amount from a single-use vial reported with the JW modifier (or JZ when none). The units must match the dose and vial, and payers audit this closely.
Why do oncology drug claims get denied?
Common reasons are missing authorization, being off the required treatment pathway, a benefit-type mismatch between medical and pharmacy, wrong drug units, or wastage-modifier errors.
How is oncology infusion billing priced?
Pricing depends on infusion volume and drug mix. Mednex reviews a sample before proposing scope. Start with a free billing audit.
Next steps
If infusion claims deny on the hierarchy, drug units, wastage, or authorization — or drug cost sits too long in A/R — a free medical billing audit will show where. Mednex reviews a sample of infusion claims and denials and sends a written summary. No patient information is needed to begin. This pairs with oncology billing, prior authorization, medical billing, and denial management; or contact Mednex.